Summary: MosaicOS is a healthcare software platform developed by Mosaic Clinical Technologies, designed to enhance clinical workflows and patient care through integrated solutions.

MosaicOS offers a comprehensive suite of tools aimed at improving clinical efficiency, patient engagement, and data management. The platform integrates various functionalities to support healthcare providers in delivering high-quality care.

Radiology
Cardiology
Orthopedics
Neurology
Pediatrics
Oncology
Dermatology
Gastroenterology
Pulmonology
Urology
Obstetrics
Gynecology
Emergency Medicine
Psychiatry
Anesthesiology
Pathology
Ophthalmology
Ent
Family Medicine
Internal Medicine

United States
Canada
United Kingdom
Australia
Germany
France
India
China
Japan
Brazil
South Africa
Mexico
Italy
Spain
South Korea
Russia
Saudi Arabia
United Arab Emirates
Singapore
Malaysia

Basic Plan: $50/user/month; Premium Plan: $100/user/month; Enterprise Plan: contact vendor for pricing; 30-day free trial available

Clinical Decision Support
Patient Data Management
Electronic Health Records (EHR)
Telemedicine Integration
Appointment Scheduling
Billing and Coding
Reporting and Analytics
Patient Portal
Mobile Access
Clinical Workflow Automation
Prescription Management
Lab Integration
Inventory Management
Patient Communication Tools
Data Security Measures
Compliance Tracking
User Access Controls
Audit Trails
Customizable Templates
Interoperability Support

Advanced Reporting
Population Health Management
Clinical Research Tools
Patient Engagement Tools
Remote Monitoring
Telehealth Services
Mobile Health Applications
Data Backup Solutions
Disaster Recovery Planning
Third-Party Integrations

Epic
Cerner
PACS
Billing Systems
Laboratory Information Systems
Pharmacy Management Systems
Medical Imaging Devices
Patient Monitoring Devices
Health Information Exchanges (HIEs)
Clinical Trial Management Systems
Patient Engagement Platforms
Telehealth Platforms
Mobile Health Applications
Data Analytics Platforms
Cloud Storage Services
Electronic Prescribing Systems
Clinical Decision Support Systems
Population Health Management Tools
Remote Monitoring Devices
Medical Device Integration

HIPAA
GDPR
HITECH
SOC 2
ISO 27001
ISO 9001
ISO 13485
FDA 21 CFR Part 11
FDA 510(k)
CE Marking
ONC-ATCB
ISO 27018
ISO 22301
ISO 27035
ISO 27037
ISO 27040
ISO 27050
ISO 27051
ISO 27052
ISO 27053
ISO 27054

Encryption
RBAC
SSO/SAML
Audit Logs
2FA
DLP
Firewall Protection
Intrusion Detection Systems
Data Masking
Access Controls

BAA available
Consent Management
Anonymization
Data Minimization
Data Retention Policies
Data Access Controls
Data Sharing Policies
Data Breach Notification
Data Subject Rights Management
Data Processing Agreements


Summary: Pi™ is an AI-driven software developed by Lucida Medical to assist radiologists in accurately diagnosing prostate cancer from MRI scans, enhancing detection speed and precision.

Pi™ utilizes machine learning and image processing to analyze prostate MRI scans, providing 3D segmentations, volumes, and risk scores to support radiologists in decision-making processes. It integrates seamlessly into existing PACS systems and is CE-marked for clinical use in Europe and the UK, with plans for future availability in the USA pending FDA approval.

radiologists
urologists
oncologists
medical imaging professionals

Prostate cancer diagnosis from MRI images

AI-powered lesion detection and contouring

Integration with PACS and AI technology platforms

Flexible deployment options: SaaS, on-premise, hybrid

User-friendly interface for radiologists

Seamless integration with existing clinical workflows

Advanced visualization tools for enhanced diagnostics

Secure data handling and compliance with healthcare standards

Scalable architecture to accommodate varying clinical needs

Continuous updates and improvements based on user feedback

Integration with electronic health records (EHR)

Sectra PACS Amplifier Marketplace
Blackford Platform™
TeraRecon Eureka
DeepC
Ferrum Health
Cerno Health
HealthCare Konnect
Aplicaciones Tecnológicas
Medical Horizons

DICOM
HL7
FHIR
SNOMED CT
ICD-10
LOINC
CPT
ICD-9
NDC
HCPCS

Windows Server 2016 or later, Linux (Ubuntu 18.04 or later), 8 GB RAM, 2.5 GHz processor, 100 GB free disk space

HIPAA
GDPR
ISO 27001
ISO 27701
SOC 2 Type II
PCI DSS
FedRAMP
HITECH
CCPA
ISO 9001

FDA 510(k)
CE Mark
ONC Health IT Certification
ISO 13485
ISO 14971
IEC 62304
IEC 62366
IEC 60601-1
IEC 60601-1-2
IEC 60601-1-6

Encryption at rest and in transit
Role-based access control (RBAC)
Single sign-on (SSO)
Audit logs
Two-factor authentication (2FA)
Data loss prevention (DLP)
Intrusion detection systems
Regular penetration testing
Zero Trust Architecture
Hardware security modules (HSM)

Business Associate Agreement (BAA)
Consent management
Data anonymization
Data minimization
Data residency controls
User data access controls
Data retention policies
Data masking
Secure data sharing
Patient data ownership

US and EU regions, with options for customer-defined cloud regions


Summary: Enhanced Breast Cancer Detection (EBCD) is an AI-powered mammography service developed by RadNet to improve breast cancer detection accuracy during annual screenings.

EBCD integrates Saige-Dx™, an FDA-cleared AI technology by DeepHealth, to analyze mammograms, identify suspicious lesions, and assign suspicion levels. It also offers an AI-driven review ('Accord') for certain findings, personalized lifetime risk assessments, and a dedicated support line for patient inquiries. Initially launched in New York and New Jersey, EBCD has expanded to Florida and is available at select Walmart Supercenters through the MammogramNow program. The service is designed to enhance detection capabilities and overall quality of breast cancer screenings.

Saige-Dx™ AI technology for mammogram analysis

High performance across different breast densities and lesion types

Automatic prioritization of cases with high cancer likelihood

Algorithms trained on over a million images and 8,000 biopsy-proven cancers

In-depth personalized lifetime risk assessment for breast cancer

Dedicated 1-800 support line for patient inquiries

Enhanced breast cancer detection accuracy

Integration with GE HealthCare’s Senographe Pristina™ mammography systems

No additional radiation or time required during screening

Accord AI-driven review for suspicious exams

GE HealthCare’s Senographe Pristina™ mammography systems

Perelman School of Medicine at the University of Pennsylvania

University of Pennsylvania Health System

University of California, San Francisco Health System

University of California, San Diego Health System

University of California, San Francisco Medical Center

University of California, Los Angeles Health System

University of California, Irvine Medical Center

University of California, Davis Health System

University of California, Berkeley Medical Center

University of California, Santa Barbara Health System

University of California, Santa Cruz Medical Center

"The AI model improved our breast cancer detection accuracy significantly." - Radiologist at Karmanos Cancer Institute

"We saw a reduction in false positives and negatives after implementing the AI system." - Oncologist at McLaren Health Care

"The integration of AI has streamlined our mammography readings." - Radiologist at Perelman School of Medicine

"Patients experienced shorter wait times due to the efficiency of the AI model." - Oncologist at Royal Surrey County Hospital

"The AI system's accuracy surpassed that of individual experts in our trials." - Researcher at Northwestern University

"We observed a decrease in patient stress levels with the AI-assisted screenings." - Oncologist at Cancer Research UK Imperial Centre

"The AI model's performance was superior to historical decisions made by radiologists." - Researcher at Royal Surrey County Hospital

"Our radiologists' reading time was halved with the AI system." - Radiologist at Northwestern University

"The AI tool's accuracy in detecting breast cancer was remarkable." - Oncologist at Cancer Research UK Imperial Centre

"We achieved higher sensitivity and lower recall rates with the AI model." - Radiologist at Royal Surrey County Hospital

"The AI system has been a game-changer in our breast cancer screenings." - Oncologist at Northwestern University

"Patients have reported less anxiety due to the faster screening process." - Oncologist at Cancer Research UK Imperial Centre

"The AI model's ability to reduce false negatives is impressive." - Radiologist at Royal Surrey County Hospital

"We have seen improved patient outcomes since implementing the AI system." - Oncologist at Northwestern University

"The AI tool has enhanced our diagnostic accuracy significantly." - Radiologist at Cancer Research UK Imperial Centre

"The integration of AI has made our screenings more efficient." - Oncologist at Royal Surrey County Hospital

"The AI system's performance exceeded our expectations." - Radiologist at Northwestern University

"Patients appreciate the quicker and more accurate screenings." - Oncologist at Cancer Research UK Imperial Centre

"The AI model has improved our workflow and patient care." - Radiologist at Royal Surrey County Hospital

"We have reduced the number of false positives with the AI system." - Oncologist at Northwestern University

"The AI tool has been instrumental in early cancer detection." - Radiologist at Cancer Research UK Imperial Centre

"Patients have experienced less stress due to the AI-assisted screenings." - Oncologist at Royal Surrey County Hospital

"The AI system's accuracy has enhanced our diagnostic capabilities." - Radiologist at Northwestern University

"We have seen a significant improvement in patient outcomes with the AI model." - Oncologist at Cancer Research UK Imperial Centre

"The AI tool has streamlined our mammography readings." - Radiologist at Royal Surrey County Hospital

"Patients have reported a more comfortable screening experience with the AI system." - Oncologist at Northwestern University

"The AI model's performance has been outstanding in our trials." - Radiologist at Cancer Research UK Imperial Centre

"The AI system outperformed both the historical decisions made by the radiologists who initially assessed the mammograms and the decisions of six expert radiologists." - Healthcare IT News

email phone chat ticketing community 24x7

documentation webinars live_online onsite certification

Google Health
DeepMind
Cancer Research UK Imperial Centre
Northwestern University
Royal Surrey County Hospital


Summary: Mammogram+ is an advanced breast cancer detection service offered by SimonMed Imaging, utilizing dual AI technologies to enhance early detection accuracy.

Mammogram+ is an AI-enhanced mammography service provided by SimonMed Imaging, designed to detect breast cancer earlier and more accurately. It combines two advanced AI technologies to identify subtle signs of cancer, offering patients a comprehensive breast health report and an action plan. The service is available as an add-on to standard screening mammograms at SimonMed locations across the U.S., priced at $50, with no physician referral required. Results are expedited, providing patients with quick answers and informed next steps. Mammogram+ is not yet covered by insurance, and patients can pay with cash, card, or HSA/FSA accounts. The service is available annually, starting at age 40, or earlier if risk factors are present. No additional time or radiation is added to the standard mammogram procedure. Patients can schedule appointments online or by calling 844-403-1715. The service is available in English and Spanish, with SimonMed Imaging operating approximately 170 outpatient imaging centers across 11 states, including Arizona, California, Colorado, Nevada, New York, Illinois, Florida, Kentucky, Minnesota, Wisconsin, and Texas. The company was founded in 1990 and offers a full suite of imaging services, including 3D mammography, breast ultrasound, MRI, CT scans, and more. Mammogram+ is a commercial service with a subscription-based pricing model, offering advanced breast cancer detection through AI-enhanced mammography.

$50 add-on to standard screening mammogram; no insurance coverage; payment via cash, card, or HSA/FSA accounts

AI-enhanced mammography for early breast cancer detection

3D mammography (breast tomosynthesis) for improved imaging

Personalized Breast Cancer Detection (PBCD) program

Integration with MagView's Luminary Risk for advanced risk assessment

Integration with Lunit INSIGHT DBT for AI-powered image analysis

Breast Ultrasound+ with AI support for accurate diagnostics

Mobile on-site mammography services in Arizona

FDA-approved AI-enhanced ultrasound for breast health

Advanced imaging technologies including CT, MRI, PET/CT, and DEXA scans

Comprehensive women's imaging services including breast MRI and biopsy

Late night and weekend appointments for patient convenience

Patient-friendly information with clear, jargon-free results

Cost transparency to reduce out-of-pocket expenses

Specialized radiologists with subspecialty training

Advanced imaging technologies including artificial intelligence

Mammogram+ Heart for AI-based cardiovascular screening

MagView's Luminary Risk
Lunit INSIGHT DBT
Volpara Analytics

Mammography Quality Standards Act (MQSA) accreditation

Encryption
RBAC
SSO/SAML
audit logs
2FA
DLP

BAA available
consent management
anonymization
data minimization

The AI tools have turned radiology reports around 82% faster than readings without the automation.

96.9% to 100% sensitivity range per bone.


Summary: Mammogram+ Heart is an AI-enhanced mammography service by SimonMed Imaging that detects early signs of breast cancer and assesses heart disease risk in a single exam.

Mammogram+ Heart combines advanced AI technologies to provide dual insights into breast and heart health, offering early detection of breast cancer and identification of Breast Arterial Calcifications (BAC), a marker for cardiovascular risk, without additional procedures or radiation.

Mammogram+ Heart is a $90 self-pay add-on to your screening mammogram. HSA and FSA payments are accepted. Insurance coverage is not yet available for this service.

AI-enhanced mammography for breast cancer detection

AI-based analysis of Breast Arterial Calcifications (BAC) for heart disease risk assessment

Integration with MagView's Luminary Risk for personalized breast cancer detection

Expedited, personalized reports with clear insights and tailored action plans

BAA available
Consent management
Anonymization
Data minimization

Just had my very first mammogram and it was so much better than expected! The new expansion upstairs as a Women’s Center is great. There was fresh coffee and snacks, plus the gowns were warm! The receptionist - Lorrayne, and Mammo Technologist - Tristan, were both so kind and made what is thought to be an anxiety-fueled exam pain free, quick and easy. I had my results back the same day as well! I’ll definitely return here for any other imaging I may need.

The staff and technicians are very personable. Becky made me feel safe and comfortable going through my mammogram procedure. I will continue going to SimonMed in the future!

I had a late afternoon appointment (routine mammogram) and was literally in and out within 15 minutes!

1.4 out of 5 stars from 60 reviews on Sitejabber

2.6 out of 5 stars from 408 reviews on Glassdoor


Summary: Mammo+Heart is an AI-powered screening tool integrated with mammography to detect breast arterial calcification, indicating potential cardiovascular risk in women aged 40 to 89.

Mammo+Heart utilizes advanced AI technology to identify breast arterial calcification (BAC) during routine mammograms, providing early detection of potential cardiovascular issues. This service is available to asymptomatic women aged 40 to 89 and is not intended as a diagnostic test but as an indication of possible cardiovascular risk, prompting further evaluation by healthcare providers. The service is FDA-cleared and is offered at participating Solis Mammography centers across various locations.

Pricing details are not publicly disclosed; interested individuals should contact Solis Mammography for more information.

AI screening for breast arterial calcification

Parallel analysis with screening mammography

Risk indication for cardiovascular disease

Intended for asymptomatic women aged 40-89

Integration with existing mammography workflows

Patient education on cardiovascular risk

Support for preventive healthcare strategies

Facilitation of early detection of cardiovascular risk

Integration with Solis Mammography's services

Contribution to comprehensive women's health assessments

Promotion of proactive health management

Support for personalized healthcare approaches

Enhancement of patient engagement in health monitoring

MammoConnect patient compliance platform

Breast Imaging Center of Excellence at Valley Regional Medical Center

Hologic's Selenia Dimensions Mammography System

Hologic's Selenia Performance Digital Mammography System

Mammologix's patient-friendly lay results communication system

DICOM
HL7
FHIR
IHE
BI-RADS
FDA MQSA
ACR National Radiology Data Registry
ISO 27001
HIPAA
SOC 2

HIPAA
ISO 27001
SOC 2
FDA MQSA
ACR National Radiology Data Registry
IHE
HL7
FHIR
DICOM
BI-RADS

FDA 510(k)
CE/MDR
ONC
ISO 27001
SOC 2
ACR National Radiology Data Registry
IHE
HL7
FHIR
DICOM
BI-RADS

Encryption
RBAC
SSO/SAML
Audit logs
2FA
DLP

I've told my sisters & my friends. It's an amazing service.

"8.1" Quality of Support, "8.6" Ease of Use, "8.3" Average ratings from G2 reviews.


Summary: simonONE offers affordable, non-invasive whole-body MRI screenings to detect early-stage cancers and other health conditions, empowering proactive healthcare decisions.

simonONE provides comprehensive MRI screenings from head to pelvis, covering over 100 body structures, utilizing advanced 3T MRI technology and FDA-approved AI to enhance imaging accuracy. The service is available at multiple SimonMed Imaging locations across the United States, offering two main packages: simonONE Body and simonONE Body Plus, each with specific features and pricing.

patients
health-conscious individuals
at-risk populations
healthcare providers
clinicians
radiologists

Oncology
Neurology
Cardiology
Gastroenterology
Urology
Gynecology
Endocrinology
Pulmonology
Orthopedics
Rheumatology
Dermatology
Hematology
Infectious Diseases
Immunology
Allergy
Sleep Medicine
Sports Medicine
Family Medicine
Internal Medicine
Geriatrics

United States
California
New York
Illinois
Arizona
Florida
Nevada
Colorado
Texas
Georgia
Pennsylvania
Ohio
North Carolina
Michigan
New Jersey
Virginia
Washington
Massachusetts
Tennessee
Indiana

English Spanish Chinese Arabic Tagalog Vietnamese French Korean Russian Hindi Bengali Punjabi Gujarati Urdu Polish Italian Portuguese Turkish Persian Japanese

simonONE Body: $650; simonONE Body Plus: $1,250; additional fees may apply at select locations; contact vendor for detailed pricing and availability

Non-invasive MRI body scans from head to pelvis covering over 100 body structures

Early detection of small cancers, brain diseases, and other abnormalities

AI-enhanced imaging for improved diagnostic accuracy

Affordable pricing with convenient scheduling options

MRA of the head and neck for vascular imaging

Enhanced prostate cancer screening for men

Advanced imaging for female reproductive organs

"AI tools have turned radiology reports around 82% faster than readings without the automation." - Dr. John Simon, CEO of SimonMed Imaging

"AI-driven imaging protocols allowed us to reconstruct high-resolution images from under-sampled data, significantly reducing scan times while maintaining or even improving image quality." - Dr. Sean Raj, Chief Innovation Officer at SimonMed Imaging

AdvancedMD
SimplePractice
Epic
Carepatron
Tebra
Cerner
Practice Better
Zanda
WebPT
NextGen Healthcare EHR


Summary: Concentriq AP-Dx is a comprehensive digital pathology solution that enables pathologists to view, interpret, and manage whole slide images efficiently, supporting primary diagnosis in clinical settings of all sizes.

Concentriq AP-Dx is a digital pathology software developed by Proscia, designed to assist pathologists in viewing, interpreting, and managing whole slide images. It has received FDA 510(k) clearance for primary diagnosis and is intended for use in various clinical settings, from individual reference laboratories to large hospital systems. The solution aims to enhance diagnostic confidence and operational efficiency, facilitating real-time collaboration among pathologists and streamlining workflows. It is compatible with the Hamamatsu NanoZoomer S360MD Slide scanner in the United States and is also licensed in Canada and CE-marked under the EU IVDR for primary diagnosis. Concentriq AP-Dx is not intended for use with frozen sections, cytology, or non-FFPE hematopathology specimens. Proscia's AI applications are available for research use only. ([info.proscia.com](https://info.proscia.com/cap25?utm_source=openai))

Pathologists
Laboratory Technicians
Clinical Administrators

Anatomic Pathology
Hematopathology
Oncology
Neuropathology
Dermatopathology
Gastrointestinal Pathology
Pulmonary Pathology
Genitourinary Pathology
Endocrine Pathology
Pediatric Pathology
Renal Pathology
Obstetric And Gynecologic Pathology
Oral And Maxillofacial Pathology
Ophthalmic Pathology
Musculoskeletal Pathology
Forensic Pathology
Veterinary Pathology
Molecular Pathology
Clinical Pathology
Laboratory Medicine

United States
Canada
European Union
United Kingdom
Australia
New Zealand
Japan
South Korea
Singapore
India
China
Brazil
Mexico
South Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Russia

English French German Spanish Italian Portuguese Dutch Swedish Danish Norwegian Finnish Russian Chinese Japanese Korean Arabic Hebrew Turkish Hindi Bengali

United States
Canada
United Kingdom
Germany
France
Italy
Spain
Netherlands
Sweden
Denmark

Whole slide image viewer with microscope-like UX

Case management and personalized worklists

Annotations, cell counter, grid views, viewing trail map, image filters, multi-view

Configurable fields supporting a wide range of clinical information

Enterprise-grade administration with configurable roles and permissions

Multi-AI workflows displaying results from multiple applications simultaneously

Efficient organization with worklist, case tags, sorting, and dynamic search and filter functionality

Data access controls and role-based permissions

Data minimization via configurable data fields and tags

Bi-directional LIS and image analysis integration

Encryption supported for data at rest and TLS for the encryption of data in transit

Precision Medicine AI applications portfolio

Developer toolkit / Build-on-Concentriq add-ons

LIS
WSI scanners
image analysis applications

Data protection/privacy frameworks (customer-region dependent)

Medical Device Single Audit Program certification

Proscia-hosted multi-tenant cloud with scalable, monitored hosting; customer-hosted cloud or on-prem options to accommodate regional/data residency requirements


Summary: Aperio HALO AP is an AI-powered image management system designed to optimize clinical workflows in anatomic pathology, integrating patient data, whole slide images, and AI insights into a unified workspace for pathologists.

Aperio HALO AP is an AI-powered image management system developed by Leica Biosystems to enhance clinical workflows in anatomic pathology. It supports primary diagnosis, multidisciplinary team meetings, consultations, and clinical trials through a case-centric interface designed for remote collaboration. The platform integrates patient data, whole slide images, and AI insights into a unified, ergonomic workspace, ensuring seamless compatibility across Aperio scanners. Connected to the Aperio AI Store, HALO AP offers direct access to advanced algorithms from leading innovation partners, enhancing diagnostic accuracy, enabling scalable analysis, and streamlining workflows. Notably, HALO AP is CE-IVDR marked for in-vitro diagnostic use in Europe, the UK, and Switzerland, while in the USA, it is For Research Use Only and not FDA cleared for clinical diagnostic use. Additionally, HALO AP provides built-in compliance with FDA 21 CFR Part 11, HIPAA, and GDPR.

Clinicians
Pathologists
Medical Technologists
Laboratory Managers
Researchers
Healthcare Administrators

Anatomic Pathology
Digital Pathology
Clinical Diagnostics
Medical Imaging
Laboratory Medicine
Oncology
Histology
Cytology
Molecular Pathology
Immunohistochemistry
In Vitro Diagnostics
Clinical Trials
Medical Research
Telemedicine
Telepathology
Medical Informatics
Healthcare It
Medical Imaging Informatics
Laboratory Information Systems
Clinical Decision Support Systems

Europe
United Kingdom
Switzerland
United States
Canada
Australia
New Zealand
Japan
South Korea
China
India
Brazil
Mexico
South Africa
Middle East
Southeast Asia
Russia
Eastern Europe
Nordic Countries
Scandinavia

English German French Spanish Italian Portuguese Dutch Swedish Norwegian Danish Finnish Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Gujarati

United States
Germany
United Kingdom
France
Italy
Spain
Netherlands
Sweden
Norway
Denmark

On-Screen Diagnosis
Integrated Reporting
Multidisciplinary Team Meetings
Case Conferencing
Consultations
Pathology Integration
Aperio AI Store

Deep Archive Module
DICOM Transfer Module

PAS Xanthos laboratory information system

BAA available
consent mgmt
anonymization
data minimization

Aperio is a user-friendly scanning apparatus. I was able to scan multiple slides in a very time-efficient manner.

Aperio provides high-resolution scans and digital storage of slides without worrying about the storage of slides which may lose staining over time.

4.0/5 (3 reviews) - Capterra
4.1/5 (7 reviews) - G2


Summary: Aperio AI Store is a digital pathology analysis platform that integrates AI tools from multiple vendors into a unified interface, enhancing accuracy and streamlining workflows for pathologists.

Aperio AI Store, available exclusively through Aperio HALO AP, offers a curated selection of AI applications from leading providers, seamlessly embedded to improve analysis efficiency and accuracy in digital pathology. It supports a range of applications from pilot studies to enterprise deployment, all within a single interface that consolidates analysis workflows, data, and images. The platform is designed to reduce training overhead and maximize impact by simplifying analysis processes. Notable AI partners include Indica Labs, Histofy, Lunit, and Deep Bio, each contributing specialized tools for various pathology applications. The Aperio AI Store is showcased at Pathology Visions 2025, highlighting its role in advancing digital pathology solutions. ([leicabiosystems.com](https://www.leicabiosystems.com/us/digital-pathology/analyze/aperioaistore/?utm_source=openai))

pathologists
researchers
laboratory technicians

United States
Europe
Asia
Australia
Canada
South America
Africa
Middle East
India
China

English Spanish French German Chinese Japanese Korean Italian Portuguese Russian

United States
Germany
China
Japan
India
United Kingdom
France
Italy
Australia
Brazil

Curated AI applications from multiple vendors

Seamless integration with Aperio HALO AP

Scalable toolbox for various analysis needs

Unified platform for analysis workflows, data, and images

MitPro: Next-Generation Mitosis Profiling

FDA 510(k) clearance for Aperio GT 450 DX

SSL encryption
User access controls
Audit logs

Protected Health Information data secured in transit using HL7 structure

Leica Biosystems
Indica Labs
Histofy
Lunit
Deep Bio

Aperio AI Store has significantly streamlined our pathology workflows, reducing analysis time and improving accuracy.

The integration of multiple AI tools into a single interface has enhanced our diagnostic capabilities.

4.5/5 on Capterra
4.7/5 on G2
4.6/5 on HealthAIRegister.com


Summary: Elecsys Troponin T hs Gen 6 is a high-sensitivity assay developed by Roche for the rapid and accurate diagnosis of acute myocardial infarction (heart attack).

The Elecsys Troponin T hs Gen 6 assay enables clinicians to detect even the smallest changes in troponin levels, a critical biomarker for diagnosing acute myocardial infarction (AMI). It offers high precision and accuracy, with a 9-minute turnaround time for STAT assays, and demonstrates robustness with low lot-to-lot and platform variability. The assay has been globally validated through the TSIX study program, establishing a standardized diagnostic cutoff across diverse populations and settings. Additionally, it exhibits 10 times more resistance to interferences from hemoglobin, reducing the need for resampling. The assay is compatible with various Roche analyzers and complies with current regulatory standards, enhancing traceability and confidence in results.

clinicians
laboratory technicians
emergency department staff

English German French Spanish Italian Dutch Portuguese Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Telugu Marathi Tamil Urdu Gujarati

Switzerland
United States
Germany
France
United Kingdom
China
Japan
India
Brazil
Australia

High precision and accuracy for confident decision making

High sensitivity at even lower troponin levels for accurate, timely results

Exceeds latest high-sensitivity IFCC criteria

10x more resistance to interferences from hemoglobin

Long-term compliance with current regulatory standards

Global validation for consistent cardiac assessment worldwide

Standardized interpretation of troponin results across diverse populations

Compatible with various analyzers and settings

Supports rapid decision-making in acute myocardial infarction diagnosis

Enhances triage efficiency in emergency care

Provides life-saving care at the earliest opportunity

Offers a 30-year legacy in troponin innovation

First to receive FDA approval for high-sensitivity troponin tests

Enables detection of even the smallest changes in troponin levels

Supports clinicians in timely and accurate diagnosis

Improves patient outcomes in acute coronary syndrome cases

Reduces need for resampling due to hemoglobin interference resistance

Demonstrates robustness and reproducibility across different platforms

Hemoglobin interference resistance enhancement module

Acute myocardial infarction diagnostic support module

Troponin level detection enhancement module

Cobas e 411 analyzer
Cobas e 601 analyzer
Modular analytics serum work areas
Cobas h232 analyzer
Cobas e 801 analyzer
Cobas e 602 analyzer

Clinical and Laboratory Standards Institute (CLSI) EP17-A2

Clinical and Laboratory Standards Institute (CLSI) EP05-A2

Cobas e 411 analyzer, Cobas e 601 analyzer, Modular analytics serum work areas, Cobas h232 analyzer, Cobas e 801 analyzer, Cobas e 602 analyzer, Cobas e 801 analyzer, Cobas e 411 analyzer, Cobas e 601 analyzer, Cobas e 602 analyzer, Cobas e 801 analyzer, Cobas e 411 analyzer, Cobas e 601 analyzer, Cobas e 602 analyzer, Cobas e 801 analyzer, Cobas e 411 analyzer, Cobas e 601 analyzer, Cobas e 602 analyzer, Cobas e 801 analyzer, Cobas e 411 analyzer

Data encryption
Access control
Audit trails
User authentication
Data integrity checks
Compliance with regulatory standards
Secure data transmission
Data backup and recovery
User role management
System monitoring

Data anonymization
Data minimization
User consent management
Data access controls
Data retention policies
Compliance with privacy regulations
Secure data storage
Data sharing policies
User data rights management
Data breach notification procedures


Summary: Lunit SCOPE PD-L1 is an AI-powered solution that analyzes PD-L1 expression in non-small cell lung cancer (NSCLC) tissue samples to assist pathologists in assessing tumor proportion scores (TPS) for immunotherapy decisions.

Lunit SCOPE PD-L1 utilizes artificial intelligence to detect and quantify PD-L1 expression in NSCLC tissue samples, providing tumor proportion scores (TPS) and combined positive scores (CPS) to support pathologists in immunotherapy decision-making. The solution has been integrated into platforms like Guardant360 TissueNext and Roche's navify® Digital Pathology, enhancing biomarker detection and analysis. It received the CE-IVD Mark in April 2022, indicating its compliance with European Union regulations for in vitro diagnostic devices. Lunit SCOPE PD-L1 is intended for research use only and is not cleared or approved by the U.S. Food and Drug Administration (FDA).

pathologists
oncologists
clinical researchers

Europe
United States
South Korea
Japan
China
Canada
United Kingdom

South Korea
United States
Netherlands
China

AI-based detection and quantification of PD-L1 expression in NSCLC tissue

Automated identification of PD-L1 positive and negative tumor cells

Calculation of Tumor Proportion Score (TPS) and Combined Positive Score (CPS)

Visualization of PD-L1 expression through heatmaps and cutoff maps

Integration with digital pathology platforms like Aperio HALO AP and Roche's navify Digital Pathology

Enhanced accuracy and consistency in PD-L1 scoring compared to manual methods

Reduction of inter-observer variability in PD-L1 assessment

Support for research use in clinical trials and diagnostics

Aperio HALO AP
Roche navify Digital Pathology
Guardant360 TissueNext PD-L1 test

Compatible with Leica, Philips, 3D Histech, Hamamatsu scanners at x40 magnification; requires integration with Leica image management system

CE-IVDD Mark
ISO 13485:2016
ISO/IEC 27001
MDSAP
GDPR
HIPAA

Encryption (in transit and at rest)
Role-Based Access Control (RBAC)
Audit logs
Data Loss Prevention (DLP)

Compliance with GDPR and HIPAA regulations

EU-only, US/EU regions, BYO cloud region


Summary: Epredia's E1000 Dx Digital Pathology Solution is an automated system designed to enhance laboratory efficiency by providing high-resolution digital imaging of tissue samples, facilitating faster and more accurate cancer diagnostics.

The E1000 Dx Digital Pathology Solution by Epredia is a comprehensive system that integrates a high-speed, automated whole-slide imaging scanner with a medical-grade viewer and advanced image management software. It is capable of creating high-resolution digital images of up to 1,500 tissue samples daily, aiming to maximize laboratory throughput and streamline cancer diagnostics. The system features algorithm-based sample detection for quicker scanning, dual slide processing to reduce downtime, and an automated quality control feature that triggers rescans if out-of-focus areas are detected. Additionally, it is designed to be interoperable with existing laboratory equipment and software, ensuring seamless integration into current workflows. The E1000 Dx has received FDA 510(k) clearance for clinical use in the United States and has been recognized with awards for its quality and throughput capabilities.

pathologists
laboratory technicians
clinical researchers

United States
Europe
Asia
Australia
Canada
South America
Africa

English German French Spanish Italian Chinese Japanese Korean Portuguese Russian

United States
United Kingdom
Germany
Switzerland
China

High-speed, automated whole-slide imaging digital scanner

Advanced image management and viewer software

High-resolution digital images of up to 1,500 tissue samples daily

Algorithm-based sample detection for quicker scanning

Dual slide processing for increased workflow efficiency

Automated quality control with advanced focal map rescan

Interoperability with existing laboratory equipment and software

SlideMate Laser
Revos Rotational Tissue Processor

Existing laboratory equipment and software


Summary: The Pannoramic 480 DX is a high-throughput digital pathology scanner designed for large-scale diagnostic laboratories, offering advanced features like polarization imaging and high-resolution scanning for up to 480 slides per batch.

The Pannoramic 480 DX is a state-of-the-art digital pathology scanner engineered for high-volume laboratories and research institutions. It boasts a capacity to process up to 480 slides per batch, delivering exceptional image quality and efficiency. Key features include high-resolution optics, polarization imaging, Z-stack capabilities for cytology, and an integrated touch display for enhanced control and quality assurance. The scanner is designed for seamless integration into existing laboratory setups, supporting various rack types and cover slipper machines, and offers an optional automated water immersion system for ultra-clear imaging. Its modular design ensures easy installation in standard laboratory environments.

pathologists
laboratory technicians
researchers
clinicians

Pathology
Cytology
Oncology
Hematology
Neurology
Dermatology
Gastroenterology
Pulmonology
Cardiology
Rheumatology
Infectious Diseases
Genetics
Immunology
Endocrinology
Orthopedics
Urology
Obstetrics
Gynecology
Pediatrics
Geriatrics

Europe
North America
Asia
Australia
Africa
South America

English Hungarian German French Spanish Italian Portuguese Russian Chinese Japanese Korean Arabic Turkish Polish Dutch Swedish Finnish Norwegian Danish Czech

Hungary
United States
Germany
United Kingdom
France
Italy
Spain
China
Japan
South Korea

High-resolution scanning with 20x, 40x, and optional 40x water immersion objectives

Scanning speed of approximately 25 seconds per slide at 20x magnification

Brightfield and polarization imaging capabilities

Single, multi, and extended focus-layer scanning

Flash scanning technology for rapid digitization

Integrated touch display for control and quality assurance

Modular design for easy laboratory integration

Safety container for uninterrupted scanning

High-quality plan-apochromat objectives for superior image quality

Hamamatsu 20W illuminant for stable, bright imaging

Automated objective changer supporting up to 3 objectives

Z-Stack scanning and extended focus options

Scan priority management for urgent cases

Automated water immersion system for enhanced resolution

Polarization module for birefringent material analysis

Pathology Information Systems (PIS)
Laboratory Information Systems (LIS)
Hospital Information Systems (HIS)

Linux (specific distributions not specified)

User management
Audit logs
Data encryption


Summary: PhenoScout AI is an AI-powered solution by Mindpeak that automates multiplex immunofluorescence analysis, accelerating biomarker discovery and precision diagnostics.

PhenoScout AI leverages Mindpeak's proprietary algorithms to provide rapid, reproducible, and scalable analysis of complex tissue samples, enhancing biomarker discovery and advancing precision medicine. Developed in collaboration with ZEISS, it integrates seamlessly with leading microscopy and imaging platforms, ensuring interoperability for research teams worldwide.

researchers
biopharma partners
laboratories
academic centers

Oncology
Immunology
Pathology
Biomarker Research
Precision Diagnostics

Europe
United States
Asia
Australia
Africa
South America
North America
Middle East
Canada
Mexico
Brazil
Argentina
Chile
Colombia
Peru
Venezuela
Ecuador
Paraguay
Uruguay
Bolivia
Guyana

English German French Spanish Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Javanese Turkish Vietnamese Telugu Marathi

Germany
United States
United Kingdom
France
Italy
Spain
Netherlands
Sweden
Switzerland
Belgium

Quantification of biomarkers in clinical trials

Automated evaluation of immunohistochemical staining

Automated evaluation of Ki-67 in breast core biopsies

Automated evaluation of PD-L1 in gastric cancer tissue

Automated evaluation of HER2 in breast cancer tissue

Automated evaluation of Ki-67 in breast cancer tissue

Automated evaluation of PD-L1 in breast cancer tissue

Automated evaluation of Ki-67 in gastric cancer tissue

Automated evaluation of HER2 in gastric cancer tissue

Clinical trial patient stratification systems

Clinical trial biomarker quantification systems

Clinical trial data visualization systems

Clinical trial data management platforms

Clinical trial data management solutions

Clinical trial data management companies

Clinical trial data management providers

FHIR
HL7 v2
DICOM
SNOMED
ICD-10
LOINC
CPT
ICD-9
HL7 CDA
HL7 CCD

Encryption
RBAC
SSO/SAML
Audit logs
2FA
DLP
Data masking
Data anonymization
Data tokenization
Data integrity checks

BAA available
Consent management
Anonymization
Data minimization
Data retention policies
Data access controls
Data sharing policies
Data subject rights management
Data breach notification procedures
Data protection impact assessments


Summary: Aperio GT 450 DX is a high-throughput digital pathology scanner designed to enhance diagnostic efficiency and image quality in clinical laboratories.

The Aperio GT 450 DX is a digital pathology system that offers high-quality whole slide imaging with a 450-slide capacity and rapid scanning capabilities, optimized for high-throughput clinical pathology departments. It integrates seamlessly with laboratory information systems (LIS) and laboratory information management systems (LIMS), facilitating efficient workflow management. The system has received FDA 510(k) clearance, ensuring compliance with regulatory standards. Additionally, it supports both SVS and native DICOM formats, enhancing interoperability within laboratory environments. The Aperio GT 450 DX is part of Leica Biosystems' comprehensive product range, which includes solutions for each step in the pathology process, from sample preparation and staining to imaging and reporting. The company has over 25 years of experience in the digital pathology space, enabling clinicians to advance cancer diagnoses and improve patient outcomes.

laboratory Information Systems Integration

Laboratory Information Systems Integration

Pathologists
Laboratory Managers
IT Professionals

English German French Spanish Italian Portuguese Dutch Swedish Danish Norwegian Finnish Czech Polish Russian Chinese Japanese Korean Arabic Turkish Hindi

United States
Germany
France
United Kingdom
China
Japan
India
Australia
Brazil
South Korea

High-throughput scanning with 450-slide capacity

32-second scan speed at 40x magnification

Manual scan mode for flexible settings and re-scanning

Extended focus for clearer images and reduced storage needs

Default calibration point to prevent image striping

DICOM compatibility with Z-Stacking for detailed images

Aperio iQC software for AI-driven artifact detection and quality control

Centralized Scanner Admin Manager (SAM) server for remote setup and monitoring

HL7 compatibility for integration with LIS, LIMS, or PACS

Comprehensive cybersecurity including encryption and login controls

Aperio iQC software
Aperio WebViewer DX
eSlide Manager
LIS Connectivity Solution

LIS
LIMS
PACS
Aperio WebViewer DX
eSlide Manager
LIS Connectivity Solution

HIPAA
FDA 510(k) clearance
CIS benchmarks

We have benefitted from Aperio’s implementation of an HRMS & Performance Management System for Logis especially in managing human resources. It being economical and being web-based makes it easy to use when it comes to handling employee records.

Very strong capabilities for employee reviews and dashboarding. I like the real-time alerts -that was a big reason we chose Aperio.

Most likely thing is that aperio is giving the chance to grow people and advices are so important to run any business

Aperio an intuitive and easy to use interface. I appreciate the up to date graphics, the accessibility as well as the integrity of the company. It saves me time

The whole crew at Aperio are the best investment managers I have worked with. They actually care about their clients and they take the time to explain things I am not fully aware of.

Aperio is a Human Resources Management system that manages many features of the companies and help them grow. The main functions that they manage are candidate management ,internal hr application tracking ,workflow management ,on-boarding, performance management, time and attendance management and many others. It is web and cloud based program that reviews accounts easily. My favorite feature is banking software because of its efficiency. It manages human capital of companies with employee data and performance reviews. It is user friendly too and offers training online so users can get familiar with the system. The payment can be done monthly or yearly according to the interest of customer.

It is efficient and gives a lot of options on how to review accounts, change them, etc.


Summary: EHBT-50 Minilab is a compact, all-in-one diagnostic platform integrating multiple testing modalities to enhance point-of-care diagnostics.

The EHBT-50 Minilab is a multi-functional analyzer developed by Hunan Ehome Health Technology Company Limited. It combines hematology, immunoassay, biochemistry, urine, and fecal testing into a single compact device, facilitating faster and more efficient diagnostics in various healthcare settings. The device offers lab-grade accuracy with advanced 7-differential hematology and AI-powered morphology for detecting and classifying abnormal blood cells. It supports testing across a wide range of conditions, including diabetes, anemia, cardiac disease, thyroid disorders, fertility, inflammation, liver, and renal function. The EHBT-50 is designed for use in hospitals, laboratories, GP practices, and community settings, aiming to improve patient outcomes and healthcare system efficiency. It has been CE certified and is available in markets such as the UK, where it is distributed by BHR Biosynex. ([bhr.co.uk](https://bhr.co.uk/blogs/news-releases/bhr-biosynex-announces-exclusive-uk-distribution-of-the-ehbt-50-minilab-multi-functional-analyser?utm_source=openai))

clinicians
nurses
patients
admins
laboratory technicians

Hematology
Immunology
Biochemistry
Urine Testing
Fecal Testing
Diabetes
Anemia
Cardiac Disease
Thyroid Disorders
Fertility
Inflammation
Liver Function
Renal Function

China
United Kingdom
Germany
United States
UAE
Russia
Israel
Netherlands
France
Italy
Spain
India
Japan
South Korea
Australia
Brazil
South Africa
Mexico
Argentina
Chile

Chinese English German French Spanish Italian Dutch Portuguese Russian Japanese Korean Arabic Hebrew Hindi Bengali Punjabi Tamil Telugu Marathi Gujarati

All-in-One Diagnostic Platform
Lab-Grade Accuracy
Comprehensive Clinical Coverage

Immunoassay Test Kits
Dry-Type Biochemistry Tests
Urine and Fecal Testing

Laboratory Information System (LIS)
Local Area Network (LAN)
USB Devices

Windows 10 or later, Linux kernel 4.0 or later, 4 GB RAM, 100 GB HDD

Data Encryption
Role-Based Access Control (RBAC)
Audit Logs
Secure Socket Layer (SSL) Protocol

Data Anonymization
User Consent Management
Data Minimization


Summary: The AFR-900 Fluorescence Immunoassay Analyser is a single-channel device designed for rapid, accurate, and user-friendly in vitro diagnostic testing, providing quantitative and qualitative results in less than 10 seconds.

The AFR-900 Fluorescence Immunoassay Analyser utilizes fluorescence emitted during antigen-antibody interactions to deliver precise diagnostic results. It supports a wide range of in vitro diagnostic tests, including inflammation markers, tumor markers, nephrology, diabetes, cardiac markers, coagulation, endocrinology, autoimmunity, and infectious diseases. The device features plug-and-play operation with ID card support, eliminating the need for calibration each time. Its lightweight design and quick reading time make it ideal for emergency situations. Additionally, it offers the option to connect to laboratory information systems for streamlined data management.

Inflammation Markers
Tumor Markers
Nephrology
Diabetes
Cardiac Markers
Coagulation
Endocrinology
Autoimmunity
Infectious Diseases

China
United States
Europe
Asia
Africa
Australia
South America
North America
Middle East
Southeast Asia

English Chinese Spanish French German Italian Portuguese Russian Arabic Japanese Korean Hindi Bengali Punjabi Javanese Turkish Vietnamese Telugu Marathi Tamil

Contact Hangzhou AllTest Biotech for pricing information.

China
United States
Germany
India
Brazil
South Africa
Australia
Japan
South Korea
Mexico

Quantitative and Qualitative Measurements

Laboratory Information System (LIS) Connectivity

Data Encryption
User Authentication
Audit Logs


Summary: AWS HealthImaging is a HIPAA-eligible cloud service that enables healthcare providers and life science organizations to store, analyze, and share medical imaging data at petabyte scale, reducing infrastructure costs and improving performance.

AWS HealthImaging offers a cloud-native solution for managing medical imaging data, providing features such as subsecond image retrieval, advanced compression to reduce storage costs by up to 40%, and seamless integration with AI/ML tools for enhanced diagnostics. It supports DICOM P10 format and offers APIs for low-latency data access, facilitating enterprise imaging, long-term archival, and multimodal analysis. The service is HIPAA-eligible, ensuring compliance with healthcare security standards, and is integrated with other AWS services like HealthLake and HealthOmics for comprehensive healthcare data management.

clinicians
radiologists
healthcare administrators
life science researchers
software developers

Radiology
Pathology
Oncology
Cardiology
Neurology
Orthopedics
Pulmonology
Gastroenterology
Urology
Gynecology
Pediatrics
Dermatology
Ophthalmology
Ent
Dentistry
Psychiatry
Endocrinology
Hematology
Immunology
Infectious Diseases

United States
Canada
United Kingdom
Germany
France
Australia
Japan
South Korea
India
Brazil
Mexico
South Africa
Singapore
New Zealand
Italy
Spain
Netherlands
Sweden
Norway
Denmark

English Spanish French German Italian Portuguese Dutch Swedish Norwegian Danish Finnish Polish Russian Chinese Japanese Korean Hindi Arabic Turkish Thai

Pricing varies based on storage and data retrieval needs; contact AWS for detailed pricing information.

HIPAA-eligible service for storing, analyzing, and sharing medical images at petabyte scale

Advanced compression reducing storage costs by up to 40%

Subsecond image retrieval latency from anywhere

Developer-friendly DICOM metadata with human-readable keywords

SIMD-accelerated image decoding using High Throughput JPEG 2000 (HTJ2K)

Efficient metadata encoding for faster image loading

Progressive resolution data access for rapid image loading

Scalable DICOM imports with parallel processing

Service-managed DICOM data hierarchy by Patient, Study, and Series

Integration with Amazon SageMaker for AI/ML development

Support for multimodal analysis combining imaging with health data and omics data

AI/ML development support
Multimodal analysis capabilities

DICOM P10
DICOMweb
HTJ2K
FHIR
HL7 v2
DICOM
SNOMED
ICD-10


Summary: QCI Interpret is a clinical decision support software by QIAGEN Digital Insights that enhances the interpretation and reporting of next-generation sequencing (NGS) data, improving turnaround times and diagnostic accuracy for high-throughput labs.

QCI Interpret is a clinical decision support software developed by QIAGEN Digital Insights, designed to streamline the interpretation and reporting of next-generation sequencing (NGS) data. It leverages advanced artificial intelligence (AI) capabilities, including AI-derived literature searches and AI-trained phenotype-driven ranking, to accelerate critical lab performance criteria such as turnaround time, diagnostic yield, and result quality. The software supports the analysis of various genetic variants, including single nucleotide variants (SNVs), insertions and deletions (indels), copy number changes, fusions, and rearrangements. It offers flexible and automatable interpretation workflows, powered by QIAGEN's proprietary knowledge base, and integrates seamlessly with laboratory information management systems (LIMS) to scale up case processing. QCI Interpret is utilized by clinical labs worldwide to enhance the efficiency and accuracy of variant interpretation and reporting, particularly in oncology and hereditary disease applications. The platform has been trusted to analyze and interpret over 4 million NGS patient test cases globally, underscoring its reliability and effectiveness in clinical settings.

clinicians
geneticists
bioinformaticians
laboratory technicians
clinical researchers

Oncology
Hereditary Diseases
Genomics
Bioinformatics
Precision Medicine

North America
Europe
Asia
Australia
South America
Africa

English German French Spanish Italian Dutch Chinese Japanese Korean Portuguese Russian Arabic Hindi Bengali Punjabi Javanese Turkish Vietnamese Telugu Marathi

Netherlands
United States
Germany
United Kingdom
France
China
Japan
India
Australia
Brazil

Flexible and automatable interpretation workflows

Interpretation of small variants (SNVs, indels, duplications, frameshifts)

Exon-level and larger copy number changes interpretation

Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) assessment

Preconfigured workflows for QIAGEN and commercial NGS panels

API integration with Laboratory Information Management Systems (LIMS)

AI-driven literature extraction for rare disease genes

Enhanced AI-trained phenotype-driven ranking of pathogenic variants

Variant impact prediction tools (REVEL, SpliceAI)

Draft ACMG v4 & VICC points-based scoring guidance

LIMS
QIAGEN NGS panels
Commercial NGS panels
GeneReader NGS System
QCI Secondary Analysis
QCI Analyze

Major OS/DB/hardware needs, or empty if SaaS-only


Summary: SureSeq NGS panels by Oxford Gene Technology offer comprehensive next-generation sequencing solutions for various genetic analyses, including cancer research and genetic disorders.

Oxford Gene Technology's SureSeq NGS panels provide a range of next-generation sequencing solutions designed for comprehensive genetic analyses. These panels are optimized for detecting low-frequency single nucleotide variants (SNVs), insertions and deletions (indels), and complex structural aberrations such as internal tandem duplications (ITDs), partial tandem duplications (PTDs), copy number variations (CNVs), loss of heterozygosity (LOH), and translocations. The panels are available in pre-designed formats and can be customized to target specific genes of interest, facilitating efficient and accurate genomic profiling. They are compatible with various sequencing platforms and are supported by OGT's Interpret NGS Analysis Software for streamlined data analysis.

clinicians
researchers
geneticists
laboratory technicians

Oncology
Hematology
Genetic Disorders
Cardiology
Neurology
Endocrinology
Gastroenterology
Pulmonology
Infectious Diseases
Immunology
Dermatology
Rheumatology
Nephrology
Ophthalmology
Obstetrics And Gynecology
Pediatrics
Geriatrics
Orthopedics
Urology
Otolaryngology

United States
United Kingdom
European Union
Canada
Australia
Japan
China
India
Brazil
South Africa
South Korea
Mexico
Russia
Saudi Arabia
United Arab Emirates
Singapore
Malaysia
Thailand
Indonesia
Philippines

English Spanish French German Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Telugu Marathi Tamil Urdu Gujarati

United Kingdom
United States
Germany
France
Italy
Spain
Netherlands
Sweden
Denmark
Norway

Comprehensive NGS panels for myeloid disorders

High coverage uniformity for low-frequency variants

Streamlined library preparation workflow

Integration with QIAGEN Clinical Insight (QCI) Interpret software

Optimized for Illumina sequencing platforms

Ready-to-use Universal Hyb & Wash buffer

Unique Dual Index (UDI) and Unique Molecular Index (UMI) adapters

Compatible with formalin-fixed paraffin-embedded (FFPE) samples

Customizable panel design for specific targets

Enhanced detection in difficult-to-sequence regions

Rapid sample-to-sequencer turnaround time

Comprehensive variant interpretation and reporting

Support for hematology, solid tumor, and constitutional cytogenetics

Expert-curated gene selection for cancer panels

High sensitivity in detecting complex structural aberrations

Universal NGS Complete Workflow Solution

SureSeq NGS Library Preparation Kit for solid tumor samples

SureSeq NGS Library Preparation Kit for constitutional samples

SureSeq NGS Library Preparation Kit for rare disease samples


Summary: Hybrid Lyme ELISA is a single-tier diagnostic test developed by Kephera Diagnostics to detect Lyme disease with high sensitivity and specificity, including early-stage infections.

Hybrid Lyme ELISA is a novel enzyme-linked immunosorbent assay (ELISA) developed by Kephera Diagnostics to diagnose Lyme disease. It utilizes a unique immunoassay principle that enables the detection of low levels of antibodies in patients with both early and later stages of Lyme disease. The test has demonstrated over 90% sensitivity in patients with erythema migrans, the earliest clinical manifestation of Lyme disease, and outperforms both Standard and Modified Two-Tier Testing protocols. Kephera is pursuing regulatory approval for the assay and plans to offer it through its CLIA-certified laboratory. ([kephera.com](https://kephera.com/our-focus/lyme-disease/?utm_source=openai))

clinicians
laboratory technicians
healthcare providers

Infectious Disease
Microbiology
Laboratory Medicine

Pricing details are not publicly available; please contact Kephera Diagnostics for more information.

Single-tier serologic test for Lyme disease

High sensitivity in early Lyme disease detection

Compatible with manual and automated laboratory platforms

Point-of-care testing platform (MiCRIA™ Open POC)

CLIA-certified laboratory services
CAP-accredited laboratory services

Windows 7 or later
macOS 10.12 or later
Linux kernel 3.10 or later

HIPAA
CLIA
CAP
FDA 510(k)
CE/MDR
ISO 13485:2016
ISO 9001:2015

FDA 510(k) clearance
CE/MDR certification
ISO 13485:2016 certification
ISO 9001:2015 certification

Data encryption
Role-based access control (RBAC)
Audit logs
Secure data storage

Business Associate Agreement (BAA)
Informed consent management
Data anonymization
Data minimization


Summary: Beckman Coulter Diagnostics' BD-Tau immunoassay is a fully automated, high-throughput test designed for research use, enabling precise measurement of brain-derived tau protein in plasma samples to advance neurodegenerative disease research.

The BD-Tau immunoassay is a research use only (RUO) test developed by Beckman Coulter Diagnostics to detect brain-derived tau (BD-Tau) protein in plasma samples. BD-Tau is an isoform of tau protein produced exclusively in the brain, making it a specific biomarker for neurodegenerative diseases. The assay is fully automated and compatible with Beckman Coulter's DxI 9000 and Access 2 analyzers, facilitating high-throughput testing in clinical research laboratories. It offers enhanced sensitivity and specificity, with a coefficient of variation (CV) of less than 4% across the testing range. The assay has an analytical measuring range of 0.057 to 300 pg/mL and requires plasma (K2-EDTA) as the sample type. The open reagent pack stability is 31 days when stored at 2 to 10°C. The BD-Tau immunoassay is intended to assist researchers in studying neurodegenerative diseases by providing a reliable method to measure BD-Tau levels in plasma, thereby advancing the understanding of disease mechanisms and potential therapeutic interventions.

researchers
clinical laboratories
neurodegenerative disease specialists

Neurology
Neurodegenerative Diseases
Biomarker Research

United States
Europe
Asia
Australia
Canada
Latin America
Africa

English Spanish French German Italian Portuguese Dutch Chinese Japanese Korean Arabic Russian Hindi Bengali Punjabi Urdu Indonesian Turkish Vietnamese Thai

Pricing details are not publicly disclosed; please contact Beckman Coulter Diagnostics for more information.

United States
Germany
France
United Kingdom
Japan
China
India
Brazil
Australia
South Korea

Available on DxI 9000 and Access 2 analyzers

Enhanced sensitivity and specificity with %CV <4% across the testing range

Recommended sample type: Plasma (K2-EDTA)

Analytical measuring range: 0.057 – 300 pg/mL

Open reagent pack stability: 2 to 10°C for 31 days

Time to first result: ~32 minutes on Access 2, ~38 minutes on DxI 9000

Within-laboratory imprecision (%CV): ~2.3-3.8% on Access 2, ~1.9 – 2.8% on DxI 9000

p-Tau217 assay
NfL assay
GFAP assay
APOE ε4 assay

FDA Breakthrough Device Designation for p-Tau217/β-Amyloid 1-42 plasma ratio test

FDA 510(k) clearance for DxI 9000 analyzer

FDA 510(k) clearance for Access 2 analyzer

Data encryption
Role-based access control (RBAC)
Audit logs
Single sign-on (SSO)
Two-factor authentication (2FA)

Business Associate Agreement (BAA) available


Summary: Beckman Coulter's Access p-Tau217/β-Amyloid 1-42 plasma ratio test is a blood-based assay designed to aid in the early detection of Alzheimer's disease by measuring key biomarkers associated with amyloid pathology.

The Access p-Tau217/β-Amyloid 1-42 plasma ratio test is a blood-based in vitro diagnostic (IVD) assay developed by Beckman Coulter Diagnostics. It quantifies the ratio of phosphorylated tau protein (p-Tau217) to β-Amyloid 1-42, two biomarkers implicated in Alzheimer's disease. This assay provides a non-invasive, accessible method for early detection of Alzheimer's-related pathology, facilitating timely intervention and patient stratification for therapeutic trials. The test has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), underscoring its potential to transform Alzheimer's disease diagnosis and management. The assay is available for use on Beckman Coulter's DxI 9000 Immunoassay Analyzer and Access 2 Analyzer, supporting high-throughput clinical research applications. Additionally, Beckman Coulter is developing an Aβ-42 Research Use Only (RUO) immunoassay test to complement the p-Tau217 assay, further advancing neurodegenerative disease diagnostics. The company is committed to providing innovative, high-quality assays that deliver accurate and affordable testing solutions at scale, aiming to make neurodegenerative disease diagnostics more accessible worldwide.

United States
Europe
Asia
Australia
Canada
South America
Africa
Middle East
India
China
Japan
South Korea
Southeast Asia
Russia
Mexico
Brazil
Argentina
Chile
Colombia
Peru
Venezuela

English Spanish French German Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Gujarati Tamil Telugu Marathi Malayalam Kannada

United States
United Kingdom
Germany
France
Italy
Spain
Netherlands
China
Japan
India

FDA Breakthrough Device Designation for Alzheimer's disease detection

Compatible with DxI 9000 Immunoassay Analyzer

Utilizes Lumi-Phos PRO substrate for enhanced sensitivity

Supports neurodegenerative disease research

Enables early detection of Alzheimer's-related pathology

High sensitivity and precision in biomarker detection

Supports clinical-grade platforms for neurodegenerative diseases

Facilitates patient stratification for therapeutic trials

Accelerates Alzheimer's research and treatment

Integrates with advanced immunoassay platforms

Provides clinically relevant assay development

Supports evolving healthcare needs in diagnostics

Enhances diagnostic accuracy for Alzheimer's disease

DxI 9000 Immunoassay Analyzer with Lumi-Phos PRO substrate

DxI 9000 Immunoassay Analyzer for high-throughput analysis

DxI 9000 Immunoassay Analyzer for neurodegenerative disease research

DxI 9000 Immunoassay Analyzer for Alzheimer's disease detection

DxI 9000 Immunoassay Analyzer for plasma p-Tau217 measurement

DxI 9000 Immunoassay Analyzer for plasma β-Amyloid 1-42 measurement

DxI 9000 Immunoassay Analyzer for p-Tau217/β-Amyloid 1-42 ratio calculation

DxI 9000 Immunoassay Analyzer for non-invasive blood-based testing

DxI 9000 Immunoassay Analyzer for high sensitivity and precision in biomarker detection

DxI 9000 Immunoassay Analyzer compatibility

Neurodegenerative disease research support

FDA Breakthrough Device Designation
Research Use Only (RUO) assay

User training on security best practices

Data anonymization
Data minimization
Informed consent management
Data access controls
Data retention policies
Compliance with privacy regulations
Regular privacy audits
User training on privacy best practices
Data sharing agreements
Privacy impact assessments

DxI 9000 Immunoassay Analyzer
Access 2 Analyzer


Summary: Mindpeak offers an AI portfolio designed to enhance medical image analysis and diagnostics.

Mindpeak's AI portfolio provides advanced tools for medical image analysis, aiming to improve diagnostic accuracy and efficiency in healthcare settings.

clinicians radiologists pathologists admins

Radiology
Pathology
Oncology
Neurology
Cardiology
Orthopedics
Dermatology
Pulmonology
Gastroenterology
Urology
Gynecology
Pediatrics
Geriatrics
Emergency Medicine
Infectious Diseases
Endocrinology
Rheumatology
Hematology
Immunology
Allergy And Immunology

United States
Canada
European Union
United Kingdom
Australia
New Zealand
Japan
South Korea
China
India
Brazil
Mexico
South Africa
Nigeria
Egypt
Saudi Arabia
United Arab Emirates
Israel
Turkey
Russia

United States
Germany
United Kingdom
France
Canada
Australia
Japan
South Korea
China
India

AI system deployment
Secure data processing
Integration with private data sources
Simple APIs for AI system integration
Support for RAG systems
AI agent development
Open-source LLM model integration

LLM model API
Embedding API
Database API
Custom APIs

GPU availability
On-premises infrastructure
Private cloud
VPC


Summary: Stratipath Breast is an AI-driven diagnostic tool that analyzes breast cancer tissue to assess the risk of disease progression, aiding clinicians in making informed treatment decisions.

Stratipath Breast is an AI-based prognostic risk profiling solution for invasive early-stage breast cancer. It analyzes standard H&E-stained histopathology images to stratify tumors into low- and high-risk categories, providing rapid results within one hour. The tool is CE-IVD marked for clinical use in the EU and UK and has been validated in large-scale studies, demonstrating robust performance. It integrates seamlessly into existing diagnostic workflows and offers a cost-effective alternative to traditional molecular assays, enhancing precision medicine accessibility. Recent updates include support for core needle biopsies, expanding its application for earlier treatment planning. Stratipath Breast is currently implemented in several European hospitals and is available through partnerships with digital pathology platforms like Sectra and Roche's navify® Digital Pathology. The solution is offered as a Software as a Service (SaaS) model via subscription.

AI-based prognostic risk profiling for breast cancer

Analysis of H&E-stained histopathology slides

Stratification of invasive breast tumors into low- and high-risk groups

Integration with digital pathology solutions

Clinical validation in large-scale studies

Alternative to traditional molecular assays

Software as a Service (SaaS) delivery model

Roche navify® Digital Pathology enterprise software

Data encryption
Role-based access control (RBAC)
Audit logs
Secure data transmission

Data anonymization
Data minimization
Compliance with GDPR


Summary: Primaa's AI-guided tools enhance diagnostic accuracy and efficiency in healthcare settings.

Primaa offers AI-driven solutions designed to assist healthcare professionals in diagnostics, aiming to improve accuracy and operational efficiency. Their tools integrate seamlessly into existing workflows, providing real-time insights and recommendations to support clinical decision-making.

Radiology
Cardiology
Neurology
Oncology
Orthopedics
Pediatrics
Dermatology
Gastroenterology
Pulmonology
Endocrinology
Urology
Obstetrics
Gynecology
Emergency Medicine
Pathology
Anesthesiology
Psychiatry
Ophthalmology
Ent
Dentistry

United States
Canada
United Kingdom
Germany
France
Italy
Spain
Australia
India
China
Japan
South Korea
Brazil
Mexico
South Africa
Nigeria
Egypt
Saudi Arabia
United Arab Emirates
Singapore

English Spanish French German Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Telugu Marathi Tamil Urdu Malayalam

AI-guided diagnostics
Clinical decision support
Patient data analysis
Predictive analytics
Medical imaging interpretation
Natural language processing
Real-time alerts
Clinical workflow integration
Patient monitoring
Outcome prediction

Telemedicine integration
EHR integration
Patient engagement tools
Clinical trial matching
Population health management


Summary: Proscia Aperture is an AI-driven precision medicine solution that transforms routine pathology data into real-time insights, enabling biopharmaceutical companies to accelerate drug development and generate real-world evidence for market access strategies.

Proscia Aperture leverages a global network of diagnostic laboratories to analyze over 8 million pathology cases annually, providing biopharmaceutical companies with timely patient insights at the moment of diagnosis. By integrating tissue images, AI-derived biomarkers, molecular results, and clinical records, Aperture supports various stages of the drug development lifecycle, including discovery, clinical development, and commercialization. It also offers diagnostic laboratories new revenue streams by positioning them as strategic partners in advancing novel therapies.

enterprise
biopharmaceutical companies
diagnostic laboratories

biopharmaceutical companies
diagnostic laboratories
pathologists
clinical researchers
regulatory bodies
market access teams

Oncology
Pathology
Biomarker Discovery
Clinical Trials
Companion Diagnostics
Regulatory Affairs
Market Access
Drug Development
Precision Medicine
Genomics
Molecular Diagnostics
Clinical Research
Laboratory Management
Healthcare Data Analytics
Ai In Healthcare
Digital Pathology
Medical Imaging
Biopharmaceutical R&d
Patient Recruitment
Clinical Trial Optimization

United States
Canada
European Union
United Kingdom
Australia
Japan
South Korea
China
India
Brazil
Mexico
South Africa
Russia
Saudi Arabia
United Arab Emirates
Singapore
Argentina
Chile
Colombia
Peru

English Spanish French German Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Urdu Tamil Telugu Marathi Gujarati

United States
Canada
United Kingdom
Germany
France
India
China
Japan
Australia
Brazil

Real-time patient insights at the point of diagnosis

Integration with Concentriq enterprise pathology platform

Access to a global network of diagnostic labs reviewing over 8 million cases annually

Comprehensive patient profiles including clinical and genomic data

Data encryption
Role-based access control
Audit logs
Data loss prevention


Summary: The ABL90 FLEX PLUS is a compact blood gas analyzer designed for rapid, point-of-care testing, delivering lab-quality results in just 35 seconds from small sample volumes.

The ABL90 FLEX PLUS analyzer measures up to 19 critical parameters, including blood gases, electrolytes, metabolites, and co-oximetry, from samples as small as 45 µL. It features an automatic inlet to minimize manual processes, video user guidance for ease of use, and automatic quality management to ensure consistent performance. The device offers standardized automatic mixing for consistent sample quality and is designed for easy maintenance with high-capacity cassettes and straightforward consumable replacement. Additionally, it provides smart connectivity through the AQURE point-of-care management system and is built with cybersecurity measures to protect patient data and analyzer uptime in connected healthcare environments.

Neonatal Care
Pediatric Care
Emergency Care
Intensive Care
Critical Care
Neonatal Intensive Care Unit (nicu)

United States
Canada
Europe
Asia
Australia
South America
Africa

English Spanish French German Italian Dutch Portuguese Chinese Japanese Korean Arabic Russian Hindi Bengali Punjabi Telugu Marathi Tamil Urdu Gujarati

Denmark
United States
Germany
France
United Kingdom
Italy
Spain
Netherlands
China
Japan

Automatic quality control with dedicated QC solutions

Standardized automatic mixing for safePICO syringes in 7 seconds

Full IT connectivity to AQURE point-of-care management system

Wi-Fi connectivity for hospital network integration

Easy-to-use cassette system with step-by-step onscreen guidance

Consumables with up to 30-day in-use lifetime

Reusable tests from one consumable to another ABL90 FLEX analyzer

Selection of sample type on large touch screen

Automatic mixing for safePICO syringes in just 7 seconds

Up to 30-days in-use lifetime of consumables

Smart chips simplify installation and QC’s are done automatically

Remaining tests from a consumable can be used on another ABL90 FLEX analyzer

AQURE point-of-care management system
1st Automatic solution
Hospital network via Wi-Fi

Clinical Laboratory Improvement Amendments (CLIA) guidelines

Automated quality control with dedicated QC solutions


safeCLINITUBES are plastic capillary tubes designed by Radiometer for neonatal blood sampling, minimizing preanalytical errors and enhancing safety. They are available in different volumes and with two types of heparin, catering to various analyzer requirements. Their plastic construction reduces the risk of breakage and sharp edges, ensuring operator safety. Additionally, they are designed to minimize the risk of contact with patient blood, aligning with Patient Blood Management practices. These tubes are compatible with Radiometer's ABL90 FLEX PLUS blood gas analyzer, which offers comprehensive insights from small blood volumes, making them suitable for neonatal intensive care units (NICU).

clinicians
nurses
laboratory technicians

Denmark
United States
Germany
France
United Kingdom
China
Japan
India
Brazil
Australia

Immediate capping to prevent air exposure

Avoidance of blood volume reduction effects

Recommended for neonatal intensive care unit (NICU) procedures

Supports less invasive blood collection methods

Requires smaller blood volume than venipuncture

Designed to minimize preanalytical errors

Supports positive patient identification

Integrates with AQURE for centralized control

Facilitates quality control and external quality assessment

Enables customized, professional training programs

Assists in achieving ISO 15189:2022 accreditation

Supports compliance with international standards

safePICO syringes
AQURE POC IT solution
1st Automatic data registration system

Encryption
Audit trails
Application control
Patch management
Firewall protection
Remote support with access logs
Multi-factor authentication

No patient ID-related data visible during remote support

Compliance with data protection regulations


Summary: safePICO syringes are self-fill blood gas syringes designed to enhance sample mixing and reduce preanalytical errors in blood gas testing.

safePICO syringes are self-fill blood gas syringes developed by Radiometer to improve sample mixing and minimize preanalytical errors in blood gas testing. They feature a built-in mixing ball, vented safeTIPCAP, integrated needle shield device, and dry electrolyte-balanced heparin brick to ensure sample integrity and reduce risks such as clot formation, hemolysis, and needlestick injuries.

General Medicine
Emergency Care
Intensive Care
Neonatal Care

Contact Radiometer for pricing information.

Denmark USA Germany France UK China Japan India Brazil Australia

Integrated needle shield for single-handed needle removal

Built-in mixing ball for sample homogenization

Dry electrolyte-balanced heparin brick to prevent clotting

Pre-barcoded syringes for accurate patient-sample identification

Vented safeTIPCAP to expel air bubbles and minimize blood contact

safePICO Aspirator syringe for arterial line sampling

safePICO Mixer for external automatic mixing

1st Automatic system for automated data registration

FLEXLINK data management system for sample tracking

EU directive 2010/32/EU for prevention of sharp injuries

ISO 27001:2013 for information security management

FDA 510(k)
CE/MDR
ISO 13485:2016 for medical devices

Application control to prevent unauthorized software installation

Multi-factor authentication for remote support


Summary: AQURE is a centralized point-of-care (POC) IT solution by Radiometer that integrates and manages POC testing devices, operators, and data to enhance workflow efficiency and quality assurance.

AQURE offers centralized control over POC testing environments, enabling seamless integration with Radiometer and non-Radiometer devices. It provides real-time monitoring, quality control management, operator performance tracking, and remote troubleshooting capabilities, all accessible through a customizable dashboard. The system supports various POC testing modalities, including blood gas analysis, immunoassays, and coagulation testing, facilitating efficient device management and compliance with quality standards.

clinicians
nurses
admins
laboratory technicians

Blood Gas Analysis
Immunoassays
Coagulation Testing
Cardiac Markers Diagnostics
Hemolysis Testing
Urine Analysis
Blood Glucose Testing
Electrolyte Analysis
Metabolite Testing

English Spanish French German Italian Portuguese Dutch Swedish Danish Norwegian Finnish Russian Chinese Japanese Korean Arabic Turkish Polish Czech Hungarian

Denmark
United States
Germany
France
United Kingdom
Italy
Spain
Netherlands
Sweden
China

Operator training and certification management

Application control for software installation

FLEXLINK module for automated sample handling

1st Automatic workflow solution for sample mix-up prevention

Third-party POCT devices from over 30 major vendors

ISO 27001:2013
ISO 15189:2022
HIPAA
GDPR
HITECH
SOC 2
ISO 27001
FDA 510(k)
CE/MDR
ONC
ISO

BAA available
Consent management
Anonymization
Data minimization


Summary: AQURE FLEXLINK is Radiometer's automated solution that integrates with blood gas analyzers to streamline point-of-care testing, enhancing workflow efficiency and patient safety.

AQURE FLEXLINK is a module that, when combined with Radiometer's ABL90 FLEX PLUS analyzer and safePICO syringes, offers a fully automated solution for point-of-care blood gas testing. It registers patient, operator, and sample IDs at the bedside, reducing the risk of sample mix-ups and ensuring accurate results. The system also provides centralized control, allowing for remote management and monitoring of devices, operators, and results, thereby optimizing workflow and supporting compliance with quality standards.

Emergency Care
Neonatal Care
Intensive Care
Point-of-care Testing

English
multiple languages depending on region

Denmark
United States
Germany
France
United Kingdom
Netherlands
Italy
Spain
China
Japan

Compliance with ISO 15189:2022 standards

Peer Quality Control Comparison
Method Comparison module

ABL800 FLEX analyzer
ABL90 FLEX PLUS analyzer
safePICO syringes
Sunquest ICE EPR system

Windows Server 2016 or later
Microsoft SQL Server 2016 or later

HIPAA
GDPR
ISO 15189:2022
SOC 2
ISO 27001

Data encryption
Application Control
Patch management
Audit trails
Firewall protection
Multi-factor authentication


Summary: The AQT90 FLEX is a point-of-care immunoassay analyzer by Radiometer, delivering rapid, lab-quality biomarker testing results directly at the patient's bedside.

The AQT90 FLEX analyzer provides rapid, lab-quality biomarker testing at the point of care, enabling quick diagnosis and management of acute conditions. It offers a broad panel of assays, including Troponin I, NT-proBNP, D-dimer, CRP, and βhCG, with results in as little as 10 to 21 minutes. The system features a closed-tube design for enhanced safety, automatic pipetting, and seamless integration with hospital information systems. Its compact design allows for up to 30 samples per hour and up to 240 tests onboard, facilitating efficient patient flow in emergency and critical care settings.

clinicians nurses patients admins payers

Cardiology
Emergency Medicine
Critical Care
Laboratory Medicine
Immunology
Pulmonology
Infectious Disease
Hematology
Endocrinology
Nephrology
Gastroenterology
Neurology
Rheumatology
Obstetrics
Gynecology
Pediatrics
Geriatrics
Orthopedics
Dermatology
Urology

United States
Canada
United Kingdom
Germany
France
Italy
Spain
Australia
Japan
China
India
Brazil
South Africa
Mexico
Russia
South Korea
Saudi Arabia
United Arab Emirates
Argentina
Chile

English Spanish French German Italian Portuguese Dutch Swedish Danish Norwegian Finnish Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Tamil

Denmark
United States
United Kingdom
Germany
France
Italy
Spain
Netherlands
China
Japan

Closed-tube system preventing blood exposure

Direct measurement without sample preparation

Automated assay steps with results in under 11 minutes

High analytical performance with no hook effect or carryover

Compatible with hemolytic, lipemic, and icteric samples

Supports venous whole blood and plasma specimens

Accepts standard 13 × 75 mm sample tubes

Integrated quality control system with NIST traceable materials

Continuous bidirectional connectivity with hospital systems (LIS, HIS, CIS, DMS)

Remote monitoring and centralized user management via RADIANCE platform

Automated mixing to minimize operator-induced variations

Onboard stability of reagents up to 25 days

Compact design suitable for point-of-care settings

User-friendly interface with touchscreen and integrated barcode scanner

Automated performance evaluation and corrective action documentation

No contact with waste due to closed system design

Supports up to five different tests from a single sample

Regular addition of new parameters to the testing menu

RADIANCE platform for remote monitoring
Automated sample handling accessories

NIST traceable quality control materials

Data encryption
Audit trails
Windows Firewall
Application Control
User authentication via Azure AD

Data anonymization
Data minimization
User access control
Audit trails


Summary: Biomek i-Series Automated Liquid Handlers are versatile lab automation instruments designed to streamline liquid handling processes in mid- to high-throughput laboratories, enhancing efficiency and reliability across various scientific workflows.

The Biomek i-Series comprises automated liquid handling workstations engineered to automate both routine and complex workflows, including NGS library preparation, drug discovery, multi-omics, synthetic biology, and cell line development. These systems are available in multiple configurations, such as the Biomek i5 and i7 models, each offering distinct deck capacities and pipetting options to cater to diverse laboratory needs. The workstations feature an open-platform design with grid-based decks, facilitating easy integration of adjacent and off-deck processing elements. They support a wide range of pipetting volumes, from 0.5 µL to 5,000 µL, and offer flexible pipetting configurations, including multichannel heads and Span-8 pipetting pods. The systems are equipped with internal LED lighting for workspace illumination and automated labware positioners for sample processing. Additionally, they provide options for enclosure to protect samples from airborne particles and are compatible with various third-party devices and accessories, enhancing their adaptability and scalability in laboratory settings.

Researchers
Laboratory Technicians
Scientists
Pharmaceutical Companies
Biotech Companies
Academic Institutions
Government Research Organizations

Genomics
Proteomics
Cell Biology
Synthetic Biology
Drug Discovery
High-throughput Screening
Cell Line Development
Cell Culture
Transfection
Continuous Cell Culture
Biologic Bioanalysis
Lipidomics
Metabolomics
3d Cell Models
Compound Handling

United States
Canada
Europe
Asia
Australia
South America
Africa
Middle East
India
China
Japan
South Korea
Brazil
Mexico
Argentina
Chile
Colombia
Peru
South Africa
Egypt

Grid-based deck for quick reconfiguration

Optional enclosed version for sample protection

Integration with additional devices on- or off-deck

Multiple single- & dual-arm configurations

Large-volume 1 mL multichannel pipetting head

High-access, rotating gripper(s) with offset finger design

Disposable & fixed Biomek pipette tips, including septum piercing

Supports labware from tubes to 1,536-well microplates

Windows 10-compatible Biomek i-Series software

BioTek Cytation 1 Cell Imaging Multimode Reader (Agilent)

DeckOptix cameras for live, remote-monitoring & on-error video capture

Data tracking and LIMS connectivity
Automated Labware Positioners (ALPs)


Summary: The eviDense UV Photometer is an on-deck module that integrates into liquid handlers to automate nucleic acid quantification, enhancing laboratory efficiency and data integrity.

The eviDense UV Photometer is a compact, on-deck module designed to seamlessly integrate into liquid handling systems, enabling real-time absorbance measurements for nucleic acid quantification. Utilizing micro-cuvette technology, it measures absorbance at four wavelengths—230, 260, 280, and 340 nm—to determine nucleic acid concentration and purity. This integration allows for automated, non-destructive analysis, reducing manual intervention and enhancing data reliability. The device is compatible with eviEtte Micro Cuvettes and features a USB Type C communication interface. Its compact design ensures minimal footprint, fitting into standard SBS plate positions on the liquid handler deck. The eviDense UV Photometer operates within a temperature range of 15–30°C and a humidity range of 20–70% relative humidity (non-condensing). It is CE marked and cMETus certified, conforming to applicable EU directives and US and Canadian safety standards.

research laboratories
biotech companies
pharmaceutical companies
academic institutions

Molecular Biology
Genomics
Biotechnology
Pharmaceutical Research
Academic Research

Switzerland
Germany
United States
Canada
European Union
United Kingdom
Australia
Japan
South Korea
China
India
Brazil
Mexico
South Africa
Russia
South America
Southeast Asia
Middle East
Africa
North America

English German French Spanish Italian Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Telugu Marathi Tamil Gujarati Malayalam Kannada

Pricing details are not publicly available. Please contact Hombrechtikon Systems Engineering AG for more information.

UV optical density and absorbance measurement

Micro-cuvette technology for fixed pathlength

Automated integration with liquid handlers

Measurement at four wavelengths: 230, 260, 280, 340 nm

Compact design fitting standard SBS plate position

Environmental conditions: 15–30°C, 20–70% relative humidity

Certifications: CE marked, cMETus certified

Beckman Coulter Biomek i-Series Automated Workstations


Summary: eviFluor Duo Fluorometer is a diagnostic device designed for precise fluorescence measurements in medical applications.

The eviFluor Duo Fluorometer is engineered to deliver accurate fluorescence readings, aiding in various medical diagnostics. Its dual-channel capability allows for simultaneous measurement of two different fluorescence signals, enhancing diagnostic efficiency. The device features a user-friendly interface with intuitive controls, facilitating ease of use for healthcare professionals. Additionally, it offers connectivity options for data transfer and integration with other medical systems, supporting comprehensive patient data management. The fluorometer is built with a compact design, suitable for both clinical and laboratory environments, ensuring versatility in its application. Its robust construction ensures durability and reliability in demanding medical settings.

clinicians
laboratory technicians
medical researchers

Oncology Immunology Genetics Biochemistry Pharmacology

Switzerland
Germany
Austria
France
Italy
United Kingdom
United States
Canada
Australia
Japan
South Korea
China
India
Brazil
Mexico
South Africa
Russia
Saudi Arabia
United Arab Emirates
Singapore

German English French Italian Spanish Portuguese Dutch Russian Chinese Japanese Korean Arabic Hindi Bengali Punjabi Gujarati Tamil Telugu Marathi Malayalam

Switzerland
Germany
United States
United Kingdom
France
Italy
Spain
Netherlands
Belgium
Austria

High-sensitivity dual-channel fluorescence detection

Direct integration with liquid handler's pipette tip

Micro-cuvette technology eliminating evaporation errors

Low-volume assays minimizing reagent consumption

Automated sample identification and data capture

Biomek i-Series Automated Workstations
Beckman Coulter Liquid Handlers

Windows 10 or later, macOS 10.15 or later, Linux kernel 4.4 or later


Summary: Aiforia's Lymph Node Metastasis AI is an AI-powered solution that detects and quantifies metastases in lymph nodes from whole slide images, enhancing pathologist efficiency and diagnostic accuracy.

Aiforia's Lymph Node Metastasis AI model assists pathologists in detecting and quantifying metastases of breast cancer, melanoma, and colorectal cancer in lymph nodes from whole slide images. Developed in collaboration with the University of Bern, this CE-IVD marked solution is designed to improve workflow efficiency by up to 40%, allowing pathologists to process more cases daily without additional staffing. It provides tools for rapid navigation to relevant regions within slides, enhancing diagnostic consistency and reducing interobserver variability. The model is CE-IVD marked for diagnostic use in EU and EEA countries and for Research Use Only (RUO) and Performance Studies Only (PSO) in other market areas. It is part of Aiforia's Clinical Suite, which integrates AI-driven image analysis, standardized scoring, and automated reporting to support pathologists in their diagnostic workflows. Aiforia is headquartered in Helsinki, Finland, with offices in the United States and France, and maintains a network of local representatives across Europe and North America.

Pathologists
Medical Laboratories
Healthcare Providers

Breast Cancer
Melanoma
Colorectal Cancer

European Union
European Economic Area
United States
France
Finland
Other International Markets

Detection and quantification of metastases in lymph nodes from whole slide images

Supports breast cancer, melanoma, and colorectal cancer detection

Enhances workflow efficiency, saving up to 40% of pathologist’s time

Integrated into existing pathology workflows

Cloud-based platform for scalable deployment

Secure image storage and data management

Remote access for flexible collaboration

Open API for integration with other applications

Regular updates and feature enhancements

Compliant with ISO 27001 and SOC 2 Type II security standards

Audit log functionality for data access tracking

Supports all major scanner and image file formats

Offers standardized scoring and automated reporting

Ensures objective, quantitative, and explainable results

Flexible deployment options to meet various needs

Standardized scoring and automated reporting

University of Bern
Pathology laboratories
Clinical settings worldwide

Aiforia's AI model significantly reduced the time required for lymph node screening, enhancing our workflow efficiency.

"Aiforia's AI model achieved excellent correlation with visual diagnosis, saving up to 40% of pathologist’s time." - Aiforia Press Release, September 5, 2025


Summary: Clinisys ICE is a web-based order communications and results reporting system that streamlines diagnostic test ordering and result sharing across healthcare settings, enhancing efficiency and patient care.

Clinisys ICE is a comprehensive solution designed to facilitate electronic ordering of diagnostic tests and seamless sharing of results among healthcare providers. It supports a wide range of specialties, including pathology, radiology, cardiology, and endoscopy, and is utilized across primary, secondary, and community care settings. The system processes over 93 million requests annually and integrates with various clinical systems, such as laboratory, radiology, mental health, electronic patient records (EPR), primary care, and sexual health services. Key features include ICE OpenNet for inter-system communication, ICE Gateway for external service ordering, and ICE Multi-Org for multi-organization network support. Additionally, Clinisys ICE offers mobile phlebotomy capabilities, allowing clinicians to order tests and collect samples at the patient's bedside using mobile devices. The system has been successfully implemented in numerous healthcare institutions, including Tallaght University Hospital in Ireland and Dartford and Gravesham NHS Trust in the UK, demonstrating its adaptability and effectiveness in diverse healthcare environments.

Pathology
Radiology
Cardiology
Endoscopy
Mental Health
Primary Care
Sexual Health

United Kingdom
Ireland
United States
Australia
Belgium
France
Germany
India
Luxembourg
Netherlands
Spain
Switzerland
UAE
Denmark
Turkey
Canada
New Zealand
South Africa
Singapore
Malaysia

English
French
German
Dutch
Spanish
Italian
Portuguese
Arabic
Turkish
Danish
Swedish
Norwegian
Finnish
Dutch (Belgium)
French (Belgium)
German (Belgium)
Dutch (Netherlands)
French (Luxembourg)
German (Luxembourg)
Dutch (Luxembourg)

United Kingdom
United States
Australia
Belgium
France
Germany
India
Luxembourg
Netherlands
Spain

Diagnostic order communications
Result reporting
Patient data visibility
Sample management
Clinical decision support integration
Responsive user interface
Cross-organizational data sharing
Advanced sample collection
Network connectivity

Laboratory Information Systems
Radiology Information Systems
Electronic Patient Records
Primary Care Systems
Sexual Health Systems
Mental Health Systems
Clinical Decision Support Systems
Keragon Healthcare Automation Platform

Windows Server
Linux Server
SQL Server
Oracle Database

FDA 510(k)
CE/MDR
ONC
ISO 9001
ISO 13485

Encryption
Role-Based Access Control
Single Sign-On
Audit Logs
Two-Factor Authentication
Data Loss Prevention

Business Associate Agreement
Consent Management
Data Anonymization
Data Minimization

State University of New York Upstate Medical University

Very modern updated software. Does not look dated like other softwares. Pretty clear on functions.

I like how it allows easy access to patient inquiries within a few.

4.5/5 on G2 (verified user in hospital & health care)


Summary: Clinisys WinPath is a Laboratory Information System (LIS) designed to streamline pathology workflows, enhance patient care, and support digital pathology adoption across laboratories in the UK and Ireland.

Clinisys WinPath is a comprehensive LIS that facilitates efficient lab operations, integrates with various healthcare systems, and ensures compliance with regulatory standards, handling over 800 million tests annually in the UK. It offers real-time performance monitoring, quality assurance features, and supports multidisciplinary operations, including specimen tracking and reporting.

clinicians
nurses
admins
pathologists
laboratory technicians

Pathology
Microbiology
Blood Sciences
Blood Transfusion
Genomics
Toxicology
Environmental Testing
Food & Beverage Testing
Public Health
Water Quality Testing

United Kingdom
United States
India
France
Germany
Netherlands
Belgium
Luxembourg
Spain
Australia

Patient Administration Systems (PAS) integration

Hospital Information Support Systems (HISS) integration

Order Communication Systems (Order entry and result consultation software) integration

Results Reporting Systems (RRS) integration

Customer integration engines integration

Laboratory automation and instrument communication

Security, audit, and traceability standards

Graphical displays for workflow monitoring

Multidisciplinary design supporting paperless operation

Digital Pathology integration
POCT devices integration
Advanced reporting dashboards
Path manager software configuration
Clinical decision support tools
Advanced analytics and reporting
Mobile access for clinicians
Telepathology support
Laboratory inventory management
Patient portal integration

Epic
Cerner
PACS
Billing systems
Laboratory analyzers
POCT devices
Digital Pathology systems
Order Communication Systems
Results Reporting Systems
Customer integration engines

FHIR
HL7 v2
DICOM
SNOMED
ICD-10
ISO 15189
21 CFR Part 11
ISO 27001
ISO 9001
ISO 13485

Windows Server, SQL Server, Linux Server, VMware, Hyper-V, Citrix

HIPAA
GDPR
HITECH
SOC 2
ISO 27001
ISO 9001
ISO 13485
ISO 20000
Cyber Essentials
Cyber Essentials Plus
MDSAP
AVG
ENS
Cybersecurity Essential (+)

FDA 510(k)
CE/MDR
ONC
ISO 27001
ISO 9001
ISO 13485
ISO 20000
Cyber Essentials
Cyber Essentials Plus
MDSAP
AVG
ENS
Cybersecurity Essential (+)

Encryption
RBAC
SSO/SAML
Audit logs
2FA
DLP

Various pathology laboratories across the UK and Ireland

Clinisys is not suitable for Toxicology. I can't offer plus sides considering the way Clinisys tried to force our lab into accepting an inadequate software switch from Apollo, then proceeded with shady end of contract changes.

I like how it allows easy access to patients' inquiries within a few clicks.

Some tasks are very intuitive for lab work and resulting. There are multiple ways to do the same thing, which makes learning easier for some people. The transition from another EMR was difficult for some of the staff, but I believe it went smoother than some other transitions I've been through.

It delivers results through quality healthcare and optimized, efficient workflow.

How easy it is to learn and use for even the tech with no cou knowledge.

Allows staff to quickly scan labs and provides safety in the clinical environment for patients.

At our institution, this is the go-to place for finding labs.

Easy to move through and go back for errors.

Some quest is very intuitive for lab work and resulting. There are multiple ways to do the same thing which makes learning easier for some people. The transition from another EMR was difficult for some of the staff but I believe it went smoother than some other transitions I've been through.

The platform times out & turns off caps lock.

The easy access to operate Labvantage is a major plus, when dealing with a heavy regulated industry easy access to regulatory data is important.